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Despite undisputed therapeutic breakthroughs in
recent decades, migraine still ranks amongst the top
ten human diseases with the greatest number of years
lived with disability (1). Several factors explain this top
ranking. First, as migraine does not decrease longevity,
it can cause disability and needs to be managed during
the greater part of the subject’s lifespan. Second,
migraine is widely undertreated (2), and even the
most disabled subjects may not consult with or not be
informed by their practitioner of the optimal manage-
ment options. Third, there is no cure for migraine, and
the available preventative (i.e. disease-modifying) drug
treatments are eﬃcient in no more than 30–50% of
patients (3), and one of the most eﬀective of such treat-
ments is abandoned by one patient out of every four
because of its disabling side eﬀects (4). The therapeutic
score is higher for speciﬁc acute anti-migraine drugs,
although this largely depends on outcome measure
(headache relief versus freedom) and route of adminis-
tration (oral versus parenteral) (3).
In the pathophysiological cascade leading to the
migraine attack, activation and sensitisation of the trige-
minovascular nociceptive system can be symbolised as
being located at the narrow exit of a funnel and involves
a restricted number of pathogenic actors, among which
calcitonin gene-related peptide (CGRP), the target of the
recently introduced immune therapies for migraine. By
contrast, the factors that are at the broad entrance of the
pathogenic funnel and induce activation of the trigemi-
novascular system are multiple and combine a number of
genetic liability loci, epigenetic factors and hormonal
inﬂuences, abnormal information processing and mito-
chondrial energy reserve, cortical and subcortical mech-
anisms. Moreover, all of these can vary between patients,
over a patient’s life and over the migraine cycle (5), illus-
trating the fact that disease-modifying therapy for
migraine remains a formidable challenge for which one
single intervention will never be optimal.
Except for invasive neurostimulation in refractory
chronic cluster headache patients, non-drug treatments
have shown no superiority over the available pharma-
ceuticals to date. However, they can have some advan-
tages over such pharmaceuticals. They are well
tolerated overall and can be combined with conven-
tional drug therapies, and some of them are eﬀective
both for preventative and acute treatment.
Unfortunately, at present, a major handicap of several
non-drug therapies is that they lack evidence-based
proof of eﬃcacy. This has been critically addressed by
the contributors to this special issue, whom I would like
to thank for the quality of their reviews and for their
patience.
This special issue will start with a review of the pos-
sible pathophysiological targets of non-pharmacologi-
cal therapies of migraine. Nutraceuticals and diets will
then be examined, followed by cognitive behavioural
therapies (‘psychoceuticals’). The review on physical
therapies in headaches (‘physicoceuticals’) will precede
four articles on neurostimulation methods (‘electroceu-
ticals’). The ﬁrst three of these articles will address inva-
sive neurostimulation methods that are to be restricted
to refractory headache patients: hypothalamic deep
brain and sphenopalatine ganglion stimulation in clus-
ter headache and invasive pericranial nerve interven-
tions. The fourth of these articles summarises the
present evidence regarding non-invasive neurostimula-
tion methods in migraine. Last but not least, a review
on integrated multidisciplinary care for diﬃcult
patients will close out this issue.
We hope that you will ﬁnd here useful information
on the various interventions that are alternatives to
drug therapies and, for some of them, can be combined
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with drugs. As mentioned, the multifactorial nature of
migraine pathogenesis and clinical experience with rec-
ommended drug treatments suggest that combining dif-
ferent therapeutic strategies is likely to provide superior
beneﬁt to our patients, although admittedly this
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